SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Carnival Corp. Ltd. engages in the operation of cruise ships. It operates through the following business segments: North America Cruise Operations, Europe Cruise Operations, Cruise Support, and Tour and Others. The North America Cruise Operations segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corporation Ltd.

Carnival Corp

Geopolitical tensions involving Iran and the Strait of Hormuz, along with resulting oil-price volatility, are driving attention to Carnival as traders debate the impact of fuel costs and travel demand. The community is split between bearish concerns over continued selling and war-related disruption and bullish views that strong bookings, earnings execution, debt reduction, buybacks, and the reinstated dividend make the shares undervalued.

NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.

Nano Nuclear Energy Inc.

NNE is attracting attention as part of a volatile small-modular-reactor and nuclear-energy rotation tied to government support, AI data-center power demand, and company milestones including AFWERX awards and NRC progress. Traders remain divided between the long-term nuclear/defense opportunity and concerns about NNEs pre-revenue status, commercialization timeline, dilution risk, and recent sector weakness.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

DFINITYs collaboration with the UNDP to explore sovereign cloud and AI infrastructure pilots, including Pakistan-related development, is driving attention around ICPs potential as a decentralized alternative to major cloud providers. Traders are broadly bullish on the institutional-use-case narrative, but skeptics point to the pilots uncertain adoption, weak revenue, inflationary tokenomics, and disappointing price action.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

FDA approval of Revolution Medicines Rasonque (daraxonrasib), a first-in-class RAS-targeted therapy for metastatic pancreatic cancer, is driving attention after pivotal data showed nearly doubled survival versus chemotherapy. Traders are debating the drugs commercial potential and broader oncology platform against concerns that the approval was already priced in, high treatment costs, side effects, and a possible sell-the-news reaction.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Attention is focused on BioCrysts profitability, Orladeyo cash generation, and CEO Charlie Gayers plan to add rare-disease assets through external deals, fueling speculative buyout and acquisition talk. Traders remain divided, with bullish views citing the Orladeyo/navenibart franchise and bearish concerns centered on competition, dilution, upcoming PHVS data, and weak price action despite solid execution.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, and Asset Closure. The Retail segment includes sale of electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

Vistra is drawing attention around its quarterly results, with traders debating weak headline revenue/EPS against stronger adjusted EBITDA, reaffirmed guidance, and claims that unrealized energy-hedge lossesnot core operationsdrove the GAAP weakness. The broader bullish thesis remains AI/data-center electricity demand and long-term power contracts, while bearish traders focus on persistent selling pressure, technical deterioration, and the risk that the power-demand narrative is already priced in.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

A new REDUCE-IT Legacy post-hoc analysis presented at ESC, suggesting cardiovascular benefits may persist after icosapent ethyl is discontinued, has renewed attention around Amarins Vascepa science. Traders are split between viewing the exploratory data as supportive of the asset and dismissing it as another rehash, while Sarissas reported stake reduction and the ongoing strategic review add uncertainty.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck and Modernas personalized mRNA melanoma vaccine, used with Keytruda, met recurrence-free and distant-metastasis-free endpoints in a Phase 3 trial, drawing attention to Mercks oncology pipeline and potential to offset future Keytruda patent pressure. Traders are broadly bullish on the validation and Mercks role in the combination, while some caution that full data, overall-survival results, regulatory approval and commercial economics remain unresolved.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Speculation around LUNC supply reduction is driving attention, with traders highlighting burns, Market Module 2.0, the 1.5% tax and a possible USTC repeg; some also anticipate large burns tied to Binance or the Terraform-related litigation. Bullish holders view these developments as a potential ecosystem revival, while skeptics point to LUNCs large supply, low volume and repeated failed rallies.

Cash Cat

Robinhoods listing of Cash Cat has made it a focal point for traders who view it as the flagship meme token of the Robinhood ecosystem, with buyback-and-burn and network-fee narratives adding to the speculation. The reaction is divided between aggressive dip-buying and expectations of further adoption, and profit-taking or bearish criticism over the post-listing selloff, high spreads, and limited utility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Adicet Bio Announces FDA Clearance of IND Application for ADI-212

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has...

Here's Why You Should Add ACET Stock to Your Portfolio Now

Adicet Bio advances prula-cel in autoimmune diseases while pursuing new opportunities in prostate cancer and in vivo CAR-T.

Are Medical Stocks Lagging  Adicet Bio (ACET) This Year?

Here is how Adicet Bio, Inc. (ACET) and Agilent Technologies (A) have performed compared to their sector so far this year.

Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet

The consensus price target hints at a 301.6% upside potential for Adicet Bio (ACET). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy

Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2026. At Adicet, we...

Lipocine Appoints Michael J. Grissinger to Board of Directors

Lipocine Appoints Michael J. Grissinger to Board of Directors Lipocine Appoints Michael J. Grissinger to Board of Directors PR Newswire SALT LAKE CITY, Aug. 3, 2026 SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary...

Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord...

Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?

Here is how Adicet Bio, Inc. (ACET) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers

Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-market session. The market value of their outstanding shares is at $77.1 million.
Bio-Techne (NASDAQ:TECH) stock movedread more...

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Adicet Bio Inc

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a positive week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

ACET Adicet Bio Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest ACET News